- Home
- BCAX vs BCYC Comparison
BCAX vs BCYC Comparison
Compare BCAX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- BCYC
- Stock Information
- Founded
- BCAX 2018
- BCYC 2009
- Country
- BCAX United States
- BCYC United Kingdom
- Employees
- BCAX N/A
- BCYC N/A
- Industry
- BCAX
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- BCAX
- BCYC Health Care
- Exchange
- BCAX NYSE
- BCYC Nasdaq
- Market Cap
- BCAX 541.0M
- BCYC 566.5M
- IPO Year
- BCAX 2024
- BCYC 2019
- Fundamental
- Price
- BCAX $10.53
- BCYC $7.99
- Analyst Decision
- BCAX Strong Buy
- BCYC Buy
- Analyst Count
- BCAX 7
- BCYC 11
- Target Price
- BCAX $29.17
- BCYC $25.00
- AVG Volume (30 Days)
- BCAX 329.8K
- BCYC 277.2K
- Earning Date
- BCAX 08-16-2025
- BCYC 08-12-2025
- Dividend Yield
- BCAX N/A
- BCYC N/A
- EPS Growth
- BCAX N/A
- BCYC N/A
- EPS
- BCAX N/A
- BCYC N/A
- Revenue
- BCAX N/A
- BCYC $25,722,000.00
- Revenue This Year
- BCAX N/A
- BCYC $7.35
- Revenue Next Year
- BCAX N/A
- BCYC N/A
- P/E Ratio
- BCAX N/A
- BCYC N/A
- Revenue Growth
- BCAX N/A
- BCYC N/A
- 52 Week Low
- BCAX $7.80
- BCYC $6.10
- 52 Week High
- BCAX $28.09
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- BCYC 46.46
- Support Level
- BCAX N/A
- BCYC $8.40
- Resistance Level
- BCAX N/A
- BCYC $8.88
- Average True Range (ATR)
- BCAX 0.00
- BCYC 0.50
- MACD
- BCAX 0.00
- BCYC -0.00
- Stochastic Oscillator
- BCAX 0.00
- BCYC 24.40
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.